アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) を意味する
Clive Ballard1, Serge Gauthier, Anne Corbett
1Wolfson Centre for Age-Related Diseases, King's College London, London, UK. clive.ballard@kcl.ac.uk
Lancet (London, England)
|March 5, 2011
まとめ
アルツハイマー病は世界中で何百万人に罹患しており,その原因,診断,リスク要因の理解を深める必要がある. この概要は,最近の証拠を強調し,リスク軽減のための潜在的な戦略について議論します.
科学分野:
- 神経学 神経学とは
- 公衆衛生は公衆衛生である.
- エピデミオロジー エピデミオロジー
背景:
- アルツハイマー病 (AD) は認知症の主要な原因で,世界中で推定2400万人の人に影響を与えている.
- ADは重要な公衆衛生上の課題であり,研究優先事項としての地位を強調しています.
- 現在の治療法ではADの症状が治りますが,疾患を改変する治療法は,病原性のより深い理解を必要とします.
研究 の 目的:
- アルツハイマー病 (AD) に関する最近の証拠の概要を提供する.
- ADの流行病学,病原性,診断,治療について議論します.
- アルツハイマー病と認知機能低下の潜在的なリスク軽減戦略を探求する.
主な方法:
- 最近の証拠に関する文献レビュー.
- ADの病原性に関する現在の理解の統合.
- バイオマーカーや神経イメージングを含む診断技術の進歩を分析する.
- アルツハイマー病および認知症の特定されたリスクおよび保護因子の検討.
主要な成果:
- ADのリスクと保護因子を理解するうえで,著しい進歩を遂げました.
- バイオマーカーに関するコンセンサスの必要性のある,診断方法の継続的な開発.
- 証拠は,ADリスクを下げるための介入の可能性を示唆しています.
- 認可された治療法では,症状の緩和がもたらされるが,疾患の修正はもたらされない.
結論:
- アルツハイマー病の病気を改変する治療法の開発には,さらなる研究が不可欠です.
- 検証されたバイオマーカーパネルを含む強化された診断ツールが必要です.
- 危険因子の理解と軽減は,アルツハイマー病と認知症の負担を軽減するための鍵です.
関連する概念動画
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...